These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 20961456)

  • 21. Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis.
    Basu S; Bendavid E; Sood N
    Circ Cardiovasc Qual Outcomes; 2015 Nov; 8(6):541-51. PubMed ID: 26555122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Global and regional estimates of the effectiveness and cost-effectiveness of price increases and other tobacco control policies.
    Ranson MK; Jha P; Chaloupka FJ; Nguyen SN
    Nicotine Tob Res; 2002 Aug; 4(3):311-9. PubMed ID: 12215240
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Primary prevention of cardiovascular disease: cost-effectiveness comparison.
    Franco OH; der Kinderen AJ; De Laet C; Peeters A; Bonneux L
    Int J Technol Assess Health Care; 2007; 23(1):71-9. PubMed ID: 17234019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The cost-effectiveness of interventions designed to reduce sodium intake.
    Wang G; Labarthe D
    J Hypertens; 2011 Sep; 29(9):1693-9. PubMed ID: 21785366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determining optimal strategies for primary prevention of cardiovascular disease: systematic review, cost-effectiveness review and network meta-analysis protocol.
    Uthman OA; Al-Khudairy L; Nduka CU; Court R; Mistry H; Melendez-Torres GJ; Taylor-Phillips S; Clarke A
    Syst Rev; 2020 May; 9(1):105. PubMed ID: 32381116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Projected effect of dietary salt reductions on future cardiovascular disease.
    Bibbins-Domingo K; Chertow GM; Coxson PG; Moran A; Lightwood JM; Pletcher MJ; Goldman L
    N Engl J Med; 2010 Feb; 362(7):590-9. PubMed ID: 20089957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity.
    Forster M; Veerman JL; Barendregt JJ; Vos T
    Int J Obes (Lond); 2011 Aug; 35(8):1071-8. PubMed ID: 21224825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The importance of indirect costs in primary cardiovascular disease prevention: can we save lives and money with statins?
    Grover SA; Ho V; Lavoie F; Coupal L; Zowall H; Pilote L
    Arch Intern Med; 2003 Feb; 163(3):333-9. PubMed ID: 12578514
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Burden of Cardiovascular Diseases Among US States, 1990-2016.
    ; Roth GA; Johnson CO; Abate KH; Abd-Allah F; Ahmed M; Alam K; Alam T; Alvis-Guzman N; Ansari H; Ärnlöv J; Atey TM; Awasthi A; Awoke T; Barac A; Bärnighausen T; Bedi N; Bennett D; Bensenor I; Biadgilign S; Castañeda-Orjuela C; Catalá-López F; Davletov K; Dharmaratne S; Ding EL; Dubey M; Faraon EJA; Farid T; Farvid MS; Feigin V; Fernandes J; Frostad J; Gebru A; Geleijnse JM; Gona PN; Griswold M; Hailu GB; Hankey GJ; Hassen HY; Havmoeller R; Hay S; Heckbert SR; Irvine CMS; James SL; Jara D; Kasaeian A; Khan AR; Khera S; Khoja AT; Khubchandani J; Kim D; Kolte D; Lal D; Larsson A; Linn S; Lotufo PA; Magdy Abd El Razek H; Mazidi M; Meier T; Mendoza W; Mensah GA; Meretoja A; Mezgebe HB; Mirrakhimov E; Mohammed S; Moran AE; Nguyen G; Nguyen M; Ong KL; Owolabi M; Pletcher M; Pourmalek F; Purcell CA; Qorbani M; Rahman M; Rai RK; Ram U; Reitsma MB; Renzaho AMN; Rios-Blancas MJ; Safiri S; Salomon JA; Sartorius B; Sepanlou SG; Shaikh MA; Silva D; Stranges S; Tabarés-Seisdedos R; Tadele Atnafu N; Thakur JS; Topor-Madry R; Truelsen T; Tuzcu EM; Tyrovolas S; Ukwaja KN; Vasankari T; Vlassov V; Vollset SE; Wakayo T; Weintraub R; Wolfe C; Workicho A; Xu G; Yadgir S; Yano Y; Yip P; Yonemoto N; Younis M; Yu C; Zaidi Z; Zaki MES; Zipkin B; Afshin A; Gakidou E; Lim SS; Mokdad AH; Naghavi M; Vos T; Murray CJL
    JAMA Cardiol; 2018 May; 3(5):375-389. PubMed ID: 29641820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Economic evaluation of pharmacotherapies for smoking cessation].
    Antoñanzas F; Portillo F
    Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Burden of Cardiovascular Disease Attributable to Major Modifiable Risk Factors in Indonesia.
    Hussain MA; Al Mamun A; Peters SA; Woodward M; Huxley RR
    J Epidemiol; 2016 Oct; 26(10):515-521. PubMed ID: 27021286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Burden of Cardiovascular Disease Attributable to Modifiable Risk Factors and Cost-effectiveness Analysis of IraPEN Program in the General Population of Iran.
    Mokhtari M; Khalil D; Farzadfar F; Daroudi R; Asadi-Lari M
    Med J Islam Repub Iran; 2022; 36():73. PubMed ID: 36128278
    [No Abstract]   [Full Text] [Related]  

  • 35. [Impact of physical inactivity on mortality and the economic costs of cardiovascular deaths: evidence from Argentina].
    García CM; González-Jurado JA
    Rev Panam Salud Publica; 2017 Aug; 41():e92. PubMed ID: 28902280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The relative impact of inadequate primary and secondary prevention on cardiovascular mortality in the United States.
    Qureshi AI; Suri MF; Kirmani JF; Divani AA
    Stroke; 2004 Oct; 35(10):2346-50. PubMed ID: 15345797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease.
    Müller-Riemenschneider F; Damm K; Meinhard C; Bockelbrink A; Vauth C; Willich SN; Greiner W
    GMS Health Technol Assess; 2009 Dec; 5():Doc16. PubMed ID: 21289903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eliminating artificial trans fatty acids in Argentina: estimated effects on the burden of coronary heart disease and costs.
    Rubinstein A; Elorriaga N; Garay OU; Poggio R; Caporale J; Matta MG; Augustovski F; Pichon-Riviere A; Mozaffarian D
    Bull World Health Organ; 2015 Sep; 93(9):614-22. PubMed ID: 26478625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The burden of disease preventable by risk factor reduction in Serbia.
    Sipetić S; Bjegović-Mikanović V; Vlajinac H; Marinković J; Janković S; Terzić Z; Atanacković-Marković Z; Saulić A; Laaser U
    Vojnosanit Pregl; 2013 May; 70(5):445-51. PubMed ID: 23789282
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of China's Low Centralized Medicine Procurement Prices on the Cost-Effectiveness of Statins for the Primary Prevention of Atherosclerotic Cardiovascular Disease.
    Wang M; Liu J; Bellows BK; Qi Y; Sun J; Liu J; Moran AE; Zhao D
    Glob Heart; 2020 Jun; 15(1):43. PubMed ID: 32923337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.